If you are not happy with the results, please do another search

Serum Institute of India sells 35% shareholding in Schott Poonawala to TPG

JSA advised Serum Institute of India Private Limited (“Serum”), in its sale of 35% stake in Schott Poonawalla Private Limited (“Schott Poonawalla”) to TPG Scion Unit Trust (acting through its trustee Scion Trustee Limited) (“TPG”). Schott Poonawalla is a joint venture between Serum and the Schott group – pursuant to the proposed sale, the Schott group remains a majority shareholder in Schott Poonawalla, while Serum and TPG will hold 15.01% and 34.99%, respectively. The transaction was subject to CCI approval, which was successfully received last month. JSA was assisted by Gibson, Dunn & Crutcher LLP on the anti-bribery and anti-corruption-related aspects of the transaction.

SCHOTT Poonawalla is India’s largest injectables-focused drug containment solutions company, offering a comprehensive product portfolio of the highest quality for over two decades.

Our transaction team comprised Lead Partner & National Corporate Lead, Iqbal Khan, Partner, Devika Menon, Senior Associate, Subbalaxmi S and Associate, Gunjan Singh.

Our competition team comprised Partner and Chair, Competition Law, Nisha Kaur Uberoi, Principal Associate, Rahat Dhawan, Senior Associate, Rishi Kauntia and Associate, Cherian Chacko Manayath.

Media coverage – Business Standard

JSA advised Cygnus Medicare on its strategic acquisition of Amandeep Healthcare

Cygnus Medicare Private Limited backed by a United States based private equity firm General Atlantic, has entered into a strategic partnership with Amandeep Healthcare Private Limited, marking a significant milestone in its expansion and entry into the Punjab healthcare market. Backed by Ujala Cygnus’ strategic partners and shareholders, Amar Ujala group and General Atlantic, Ujala Cygnus has acquired a significant stake in Amandeep Healthcare Private Limited. Through this alliance, Ujala Cygnus will bring institutional scale, technology, and operational expertise to complement Amandeep Hospitals deep rooted clinical excellence, regional trust, and a legacy of compassionate care. With this alliance, Ujala Cygnus expands its network from 22 to 28 hospitals, increasing its total bed capacity from 2,000 beds to nearly 2,800 beds.

Ujala Cygnus becomes the largest private player in the Jammu and Kashmir state with a total of 400 beds across Jammu and Srinagar. Amandeep Hospitals, a trusted name in North India, continues to uphold its mission of accessible and equitable healthcare. This shared vision is rooted in the support of the Amar Ujala Group and further strengthened by General Atlantic which entered into a strategic partnership with Ujala Cygnus, backing it with strategic growth investment in April, 2024.

Our deal team comprised of Lead Partner, Siddharth Mody, Partner, Anurag Shrivastav, Senior Associate, Tanmayee Sahoo and Associate, Gavin Pereira.

Our diligence team comprised of Partner, Anurag Shrivastav, Associates, Ayush Chaturvedi, Gavin Pereira and Regan D’Mello.

Media Coverage – Business Standard

JSA Advises ELIQUENT Life Sciences and GHO Capital on its acquisition of 100% stake in Truliant Consulting

JSA advised ELIQUENT Life Sciences and GHO Capital on its 100% acquisition of Truliant Consulting Private Limited, as part of the global acquisition of its group company, Truliant Consulting LLC. ELIQUENT Life Sciences is a leading global consulting group delivering regulatory affairs, pharmacovigilance, quality and compliance solutions that support clients across therapeutic modalities, phase-based pathways and major global markets.

The integration of Truliant’s specialized knowledge and technology-driven service offerings expands ELIQUENT’s pharmacovigilance platform.

JSA assisted in all aspects of the transaction at the India level including structuring, negotiating, drafting and finalizing the definitive agreements.

The transaction team comprised of Lead Partner, Anand Lakra, Partner, Niharika Mepani, Principal Associate, Ami Shah, Associates, Rishabh Sharma, Diya Daveand Ishan Saxena.

Our employment team comprised of Partner, Sonakshi Das and Associate, Ananya Sharma.

Our taxation team comprised of Partner and Head of Practice, Direct Tax Kumarmanglam Vijay, Partner, Surajkumar Shetty and Associate, Tejasvi Shukla.

Media CoverageBusinesswire

ASG Hospital Private Limited acquires controlling stake in Prism Eye Institute Private Limited

JSA advised and assisted ASG Hospital Private Limited (ASG), a leading chain of super specialty eye hospitals and clinics in India, in connection with its acquisition in Prism Eye Institute Private Limited (Prism Institute), with a right to purchase remaining stake as per the transaction documents.

Prism Institute is a super specialty eye care hospitals based out of Mumbai, Maharashtra.

The deal involved transfer of business of eye care hospital manged by Prism Eye Institute and Research Center LLP to Prism Institute and subsequent acquisition of majority stake in Prism Institute by ASG. JSA’s assisted in advising on structuring of the transaction, due diligence, preparation, negotiation and finalization of transaction documents.

Our transaction team comprised: Partner – Rajul Bohra, Senior Associate – Priyal Jain Somvanshi, and Associate – Ishani Moulik.

Exit of Affirma Capital from Tirupati Medicare Limited.

JSA advised TBO Korea Holdings Limited and Augusta Investments Zero Pte. Ltd. (collectively, “Affirma Capital“) in the sale of its minority stake in Tirupati MedicareLimited (“Target”) to Kotak Strategic Situations Fund II and Kotak Alternate Asset Managers Limited (collectively, “Buyers”) for a consideration of (approximately) INR 1050 Crore.

The deal also involved infusion of capital by the Buyers in lieu of debentures issued by the Target, and acquisition of shares by the Buyers from the promoters of the Target. The Target (along with its group companies) is in the business of contract manufacturing and production of pharmaceutical, nutraceuticals, ayurvedic products.

JSA had previously advised Affirma Capital (previously, Standard Chartered Private Equity Managers Korea Limited) in its acquisition of shares of the Target.

Deal Value – USD 122.6 Million

Signing Date – 12th February 2025.

Media CoverageThe Economic Times

Chemfield Cellulose’s stake sale to Oji Holdings Corporation

JSA advised Chemfield Cellulose Private Limited (CCPL) and its Promoters on the divestment of a strategic stake in CCPL to Oji Holdings Corporation. The transaction is proposed to be undertaken in multiple tranches and is subject to receipt of regulatory approvals.

CCPL is India’s first and leading manufacturer of high-quality and consistent Microcrystalline Cellulose for the pharmaceutical industry.

This transaction was led by Partner – Vikram Raghani with support from Partners – Abhijeet Sonawane and Birbahadur Sachar, Principal Associate – Vwastav Ghosh, and Associates – Nishi Shah and Tavishi Chandra.

JSA advised ASG Hospital on its acquisition of Vission Eye Hospital

JSA advised ASG Hospital on its acquisition of Vission Eye Hospital, set up by Dr. Himanshu Mehta, a leading ophthalmologist.

Our transaction team comprised: Lead Partner – Siddharth Mody, Partner – Rohan Kumar, and Senior Associate – Alister Sequeira.

Our due diligence team comprised: Principal Associate – Prerana Chaudhari, Senior Associate – Alister Sequeira, and Associate – Ayush Chaturvedi.